CellSource Co., Ltd. (JP:4880) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CellSource Co., Ltd. has announced the establishment of a new subsidiary, Hybrid Medical Co., Ltd., to enhance collaboration with medical institutions in regenerative medicine, especially within orthopedics. The subsidiary will be wholly owned by CellSource and is set to begin operations in November 2024. This strategic move is expected to have a minimal impact on the company’s financial performance for the current fiscal year.
For further insights into JP:4880 stock, check out TipRanks’ Stock Analysis page.